The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly… Read More
Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action. Turning points and catalysts March 2011… Read More
News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More
CDR-Life has announced new developments to its programme of antibody-based T cell engagers (TCE) targeting intracellular tumour antigens MAGE-A4 and PRAME via the major histocompatibility complex. The first patient has been dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4. Read More
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease. Imfinzi plus… Read More
In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a… Read More
Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise… Read More
TechBio Cytomos has launched a new benchtop cell analyser called Celledonia, which uses the company’s AuraCyt platform. Celledonia has been designed to provide cell-specific insights for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs). The new technology could… Read More
Reece Armstrong speaks to Samuel Deutsch, Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: The ability of RNA therapies to use the body’s own mechanisms to… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. A leading news story this week has been the announcement of positive Phase II… Read More
News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More
Immune B cells could be used to develop cancer targeting immunotherapies, following new research by scientists at The Institute of Cancer Research, London, the University of Oxford and University of Cambridge. The scientists discovered the role of immune B cells which makes them successful at targeting tumours,… Read More
Sharad Adekar, Medical Chair Lead and Currien MacDonald, Medical Chair Director at WCG, discuss the risks and benefits of using immunotherapies to treat cancer. In the last decade, a paradigm shift has occurred in the landscape of cancer treatment1. Supported by current advances in understanding of the mechanism and pathways… Read More
Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs constitute a promising approach for treating cervical cancer, though rejection by the host’s immune system is a major hurdle. In a recent… Read More
DDW Editor Reece Armstrong speaks to Ron Alfa, CEO & Co-founder at NOETIK, about the company’s mission to utilise artificial intelligence (AI) and spatial biology to develop better immunotherapies for cancer patients. Reece A: What are some of the human limitations to current drug discovery research for immunotherapies? Ron A:… Read More
